Cargando…

Current insight into the regulation of PD-L1 in cancer

The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhuandi, Yu, Xibao, Xu, Ling, Li, Yangqiu, Zeng, Chengwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338491/
https://www.ncbi.nlm.nih.gov/pubmed/35907881
http://dx.doi.org/10.1186/s40164-022-00297-8
_version_ 1784759979271520256
author Liu, Zhuandi
Yu, Xibao
Xu, Ling
Li, Yangqiu
Zeng, Chengwu
author_facet Liu, Zhuandi
Yu, Xibao
Xu, Ling
Li, Yangqiu
Zeng, Chengwu
author_sort Liu, Zhuandi
collection PubMed
description The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint. Studying the PD-L1 regulatory pattern of tumor cells will help elucidate the molecular mechanisms of tumor immune evasion and improve cancer treatment. Recent studies have found that tumor cells regulate PD-L1 at the transcriptional, post-transcriptional, and post-translational levels and influence the anti-tumor immune response by regulating PD-L1. In this review, we focus on the regulation of PD-L1 in cancer cells and summarize the underlying mechanisms.
format Online
Article
Text
id pubmed-9338491
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93384912022-07-31 Current insight into the regulation of PD-L1 in cancer Liu, Zhuandi Yu, Xibao Xu, Ling Li, Yangqiu Zeng, Chengwu Exp Hematol Oncol Review The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint. Studying the PD-L1 regulatory pattern of tumor cells will help elucidate the molecular mechanisms of tumor immune evasion and improve cancer treatment. Recent studies have found that tumor cells regulate PD-L1 at the transcriptional, post-transcriptional, and post-translational levels and influence the anti-tumor immune response by regulating PD-L1. In this review, we focus on the regulation of PD-L1 in cancer cells and summarize the underlying mechanisms. BioMed Central 2022-07-30 /pmc/articles/PMC9338491/ /pubmed/35907881 http://dx.doi.org/10.1186/s40164-022-00297-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Liu, Zhuandi
Yu, Xibao
Xu, Ling
Li, Yangqiu
Zeng, Chengwu
Current insight into the regulation of PD-L1 in cancer
title Current insight into the regulation of PD-L1 in cancer
title_full Current insight into the regulation of PD-L1 in cancer
title_fullStr Current insight into the regulation of PD-L1 in cancer
title_full_unstemmed Current insight into the regulation of PD-L1 in cancer
title_short Current insight into the regulation of PD-L1 in cancer
title_sort current insight into the regulation of pd-l1 in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338491/
https://www.ncbi.nlm.nih.gov/pubmed/35907881
http://dx.doi.org/10.1186/s40164-022-00297-8
work_keys_str_mv AT liuzhuandi currentinsightintotheregulationofpdl1incancer
AT yuxibao currentinsightintotheregulationofpdl1incancer
AT xuling currentinsightintotheregulationofpdl1incancer
AT liyangqiu currentinsightintotheregulationofpdl1incancer
AT zengchengwu currentinsightintotheregulationofpdl1incancer